 | • レポートコード：MRC2302D132 • 出版社/出版日：Transparency Market Research / 2022年12月16日 • レポート形態：英語、PDF、130ページ • 納品方法：Eメール（受注後24時間以内） • 産業分類：医薬品 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の本調査資料では、2022年に288.6百万ドルであった世界のバルガンシクロビル市場規模が2031年には484.1百万ドルとなり、予測期間の間に年平均4.6％増加すると展望しています。本資料では、バルガンシクロビルの世界市場について徹底調査し、序論、仮定・調査方法、エグゼクティブサマリー、市場概要、市場展望、患者年齢別（成人患者、小児患者）分析、用途別（臓器移植、サイトメガロウイルス網膜炎）分析、流通チャネル別（病院薬局、小売薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などを掲載しています。本資料は、Endo International plc、Dr. Reddy's Laboratories AG、F. Hoffmann-La Roche AG、Cipla Limited、Alniche Life Sciences Pvt. Ltd.、Anthem Biosciences Private Limited、Merck & Co., Inc.、Panacea Biotec Ltd.、Camber Pharmaceuticals, Inc.、Healthiza Lifescience Private Limitedなどの企業情報を収録しています。 ・序論 ・仮定・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場展望 ・世界のバルガンシクロビル市場規模：患者年齢別 - 成人患者における市場規模 - 小児患者における市場規模 ・世界のバルガンシクロビル市場規模：用途別 - 臓器移植における市場規模 - サイトメガロウイルス網膜炎における市場規模 ・世界のバルガンシクロビル市場規模：流通チャネル別 - 病院薬局チャネルの市場規模 - 小売薬局チャネルの市場規模 ・世界のバルガンシクロビル市場規模：地域別 - 北米のバルガンシクロビル市場規模 - ヨーロッパのバルガンシクロビル市場規模 - アジア太平洋のバルガンシクロビル市場規模 - 中南米のバルガンシクロビル市場規模 - 中東・アフリカのバルガンシクロビル市場規模 ・競争状況 |
Valganciclovir Market – Scope of Report
TMR’s report on the global valganciclovir market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global valganciclovir market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global valganciclovir market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the valganciclovir market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global valganciclovir market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global valganciclovir market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global valganciclovir market.
The report delves into the competitive landscape of the global valganciclovir market. Key players operating in the global valganciclovir market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global valganciclovir market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market valganciclovir.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Valganciclovir Market
4. Market Overview
4.1. Introduction
4.1.1. Patient Age Group
4.1.2. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Valganciclovir Market Analysis and Forecast, 2017–2031
4.3.1. Global Valganciclovir Market Revenue Projection (US$ Mn)
5. Market Outlook
5.1. Valganciclovir Virus Disease Prevalence
5.2. Key Industry Development
5.3. COVID-19 Impact Analysis
6. Global Valganciclovir Market Analysis and Forecast, by Patient Age Group
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Global Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
6.3.1. Adult Patients
6.3.2. Pediatric Patients
6.4. Global Valganciclovir Market Attractiveness Analysis, by Patient Age Group
7. Global Valganciclovir Market Analysis and Forecast, by Application
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Global Valganciclovir Market Value Forecast, by Application, 2017–2031
7.3.1. Organ Transplant
7.3.2. Cytomegalovirus Retinitis
7.4. Global Valganciclovir Market Attractiveness Analysis, by Application
8. Global Valganciclovir Market Analysis and Forecast, by Distribution Channel
8.1. Key Findings/Developments
8.2. Introduction & Definition
8.3. Global Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.4. Global Valganciclovir Market Attractiveness Analysis, by Distribution Channel
9. Global Valganciclovir Market Analysis and Forecast, by Region
9.1. Geographical Representation
9.2. Global Valganciclovir Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Global Valganciclovir Market Attractiveness Analysis, by Region
10. North America Valganciclovir Market Analysis and Forecast
10.1. North America Valganciclovir Market Value Share Analysis, by Country, 2017–2031
10.2. North America Valganciclovir Market Value Forecast, by Country, 2017–2031
10.2.1. U.S.
10.2.2. Canada
10.3. North America Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
10.4. North America Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
10.4.1. Adult Patients
10.4.2. Pediatric Patients
10.5. North America Valganciclovir Market Value Share Analysis, by Application, 2021–2031
10.6. North America Valganciclovir Market Value Forecast, by Application, 2017–2031
10.6.1. Organ Transplant
10.6.2. Cytomegalovirus Retinitis
10.7. North America Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
10.8. North America Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
10.8.1. Hospital Pharmacies
10.8.2. Retail Pharmacies
10.9. North America Valganciclovir Market Attractiveness Analysis (2022–2031)
10.9.1. By Country
10.9.2. By Patient Age Group
10.9.3. By Application
10.9.4. By Distribution Channel
11. Europe Valganciclovir Market Analysis and Forecast
11.1. Europe Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031
11.1.1. Germany
11.1.2. France
11.1.3. U.K.
11.1.4. Spain
11.1.5. Italy
11.1.6. Rest of Europe
11.2. Europe Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
11.3. Europe Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
11.3.1. Adult Patients
11.3.2. Pediatric Patients
11.4. Europe Valganciclovir Market Value Share Analysis, by Application, 2021–2031
11.5. Europe Valganciclovir Market Value Forecast, by Application, 2017–2031
11.5.1. Organ Transplant
11.5.2. Cytomegalovirus Retinitis
11.6. Europe Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
11.7. Europe Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.8. Europe Valganciclovir Market Attractiveness Analysis (2022–2031)
11.8.1. By Country/Sub-region
11.8.2. By Patient Age Group
11.8.3. By Application
11.8.4. By Distribution Channel
12. Asia Pacific Valganciclovir Market Analysis and Forecast
12.1. Asia Pacific Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031
12.1.1. China
12.1.2. Japan
12.1.3. India
12.1.4. Australia & New Zealand
12.1.5. Rest of Asia Pacific
12.2. Asia Pacific Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
12.3. Asia Pacific Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
12.3.1. Adult Patients
12.3.2. Pediatric Patients
12.4. Asia Pacific Valganciclovir Market Value Share Analysis, by Application, 2021–2031
12.5. Asia Pacific Valganciclovir Market Value Forecast, by Application, 2017–2031
12.5.1. Organ Transplant
12.5.2. Cytomegalovirus Retinitis
12.6. Asia Pacific Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
12.7. Asia Pacific Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.8. Asia Pacific Valganciclovir Market Attractiveness Analysis (2022–2031)
12.8.1. By Country/Sub-region
12.8.2. By Patient Age Group
12.8.3. By Application
12.8.4. By Distribution Channel
13. Latin America Valganciclovir Market Analysis and Forecast
13.1. Latin America Valganciclovir Market Value Forecast, by Country/Sub-region, 2017-2027
13.1.1. Brazil
13.1.2. Mexico
13.1.3. Rest of Latin America
13.2. Latin America Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
13.3. Latin America Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
13.3.1. Adult Patients
13.3.2. Pediatric Patients
13.4. Latin America Valganciclovir Market Value Share Analysis, by Application, 2021–2031
13.5. Latin America Valganciclovir Market Value Forecast, by Application, 2017–2031
13.5.1. Organ Transplant
13.5.2. Cytomegalovirus Retinitis
13.6. Latin America Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
13.7. Latin America Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
13.7.1. Hospital Pharmacies
13.8. Latin America Valganciclovir Market Attractiveness Analysis (2022–2031)
13.8.1. By Country/Sub-region
13.8.2. By Patient Age Group
13.8.3. By Application
13.8.4. By Distribution Channel
14. Middle East & Africa Valganciclovir Market Analysis and Forecast
14.1. Middle East & Africa Valganciclovir Market Value Forecast, by Country/Sub-region, 2017–2031
14.1.1. GCC Countries
14.1.2. South Africa
14.1.3. Rest of Middle East & Africa
14.2. Middle East & Africa Valganciclovir Market Value Share Analysis, by Patient Age Group, 2021–2031
14.3. Middle East & Africa Valganciclovir Market Value Forecast, by Patient Age Group, 2017–2031
14.3.1. Adult Patients
14.3.2. Pediatric Patients
14.4. Middle East & Africa Valganciclovir Market Value Share Analysis, by Application, 2021–2031
14.5. Middle East & Africa Valganciclovir Market Value Forecast, by Application, 2017–2031
14.5.1. Organ Transplant
14.5.2. Cytomegalovirus Retinitis
14.6. Middle East & Africa Valganciclovir Market Value Share Analysis, by Distribution Channel, 2021–2031
14.7. Middle East & Africa Valganciclovir Market Value Forecast, by Distribution Channel, 2017–2031
14.7.1. Hospital Pharmacies
14.7.2. Retail Pharmacies
14.8. Middle East & Africa Valganciclovir Market Attractiveness Analysis (2022–2031)
14.8.1. By Country/Sub-region
14.8.2. By Patient Age Group
14.8.3. By Application
14.8.4. By Distribution Channel
15. Competition Landscape
15.1. Competition Matrix
15.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.2.1. Endo International plc (HQ, Business Segments, Employee Strength)
15.2.1.1. Company Details
15.2.1.2. Company Description
15.2.1.3. Business Overview
15.2.1.4. SWOT Analysis
15.2.1.5. Financial Analysis
15.2.1.6. Strategic Overview
15.2.2. Dr. Reddy’s Laboratories AG (HQ, Business Segments, Employee Strength)
15.2.2.1. Company Details
15.2.2.2. Company Description
15.2.2.3. Business Overview
15.2.2.4. SWOT Analysis
15.2.2.5. Strategic Overview
15.2.3. F. Hoffmann-La Roche AG (HQ, Business Segments, Employee Strength)
15.2.3.1. Company Details
15.2.3.2. Company Description
15.2.3.3. Business Overview
15.2.3.4. SWOT Analysis
15.2.3.5. Strategic Overview
15.2.4. Cipla Limited (HQ, Business Segments, Employee Strength)
15.2.4.1. Company Details
15.2.4.2. Company Description
15.2.4.3. Business Overview
15.2.4.4. SWOT Analysis
15.2.4.5. Strategic Overview
15.2.5. Alniche Life Sciences Pvt. Ltd. (HQ, Business Segments, Employee Strength)
15.2.5.1. Company Details
15.2.5.2. Company Description
15.2.5.3. Business Overview
15.2.5.4. SWOT Analysis
15.2.5.5. Financial Analysis
15.2.5.6. Strategic Overview
15.2.6. Anthem Biosciences Private Limited (HQ, Business Segments, Employee Strength)
15.2.6.1. Company Details
15.2.6.2. Company Description
15.2.6.3. Business Overview
15.2.6.4. SWOT Analysis
15.2.6.5. Financial Analysis
15.2.6.6. Strategic Overview
15.2.7. Merck & Co., Inc. (HQ, Business Segments, Employee Strength)
15.2.7.1. Company Details
15.2.7.2. Company Description
15.2.7.3. Business Overview
15.2.7.4. SWOT Analysis
15.2.7.5. Financial Analysis
15.2.7.6. Strategic Overview
15.2.8. Panacea Biotec Ltd. (HQ, Business Segments, Employee Strength)
15.2.8.1. Company Details
15.2.8.2. Company Description
15.2.8.3. Business Overview
15.2.8.4. SWOT Analysis
15.2.8.5. Financial Analysis
15.2.8.6. Strategic Overview
15.2.9. Camber Pharmaceuticals, Inc. (HQ, Business Segments, Employee Strength)
15.2.9.1. Company Details
15.2.9.2. Company Description
15.2.9.3. Business Overview
15.2.9.4. SWOT Analysis
15.2.9.5. Financial Analysis
15.2.9.6. Strategic Overview
15.2.10. Healthiza Lifescience Private Limited (HQ, Business Segments, Employee Strength)
15.2.10.1. Company Details
15.2.10.2. Company Description
15.2.10.3. Business Overview
15.2.10.4. SWOT Analysis
15.2.10.5. Financial Analysis
15.2.10.6. Strategic Overview